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Laboratorio de Taxonomía, Servicio de Bacteriología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, SpainAbstractSpecies of the Burkholderia cepacia complex are associated with opportunistic infection in patients with cystic ﬁbrosis. For years now, B.
multivorans and B. cenocepacia have been the most frequently isolated species within the complex in such patients. However, between
2008 and 2012, the overall incidence of these species in Spain (17.7% and 12.5% respectively) was overtaken by that of B. contaminans
(36.5%). The population structure of B. contaminans isolates from Spanish patients with cystic ﬁbrosis was analysed using multilocus
sequence typing and pulsed-ﬁeld gel electrophoresis (PFGE). Three major known sequence types (ST102, ST404 and ST482) and a new
one (ST771) were identiﬁed among 59 isolates. In addition, PFGE detected 17 pulsotypes. Susceptibility to antibiotics was examined using
the Etest. Cotrimoxazole and ceftazidime were the most active antibiotics against B. contaminans, inhibiting growth in 88% and 86% of the
isolates, respectively. In addition, this species showed less resistance to most of the antibiotics tested than did either B. multivorans or B.
cenocepacia isolates recovered from similar Spanish patients.
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E-mail: mjmedina@isciii.esIntroductionMany pathogens colonize and infect the respiratory tract of
patients with cystic ﬁbrosis (CF) [1], a genetically inherited
disease that affects 1 in 2500 to 4000 live births among the
white population [2]. The bacteria of the Burkholderia cepacia
complex (Bcc) are widespread in the environment, but in
people with CF, they may behave as opportunistic pathogens
[3]. The complex currently consists of 17 closely related spe-
cies, most of which have been isolated from the sputum of
patients with CF; B. multivorans and B. cenocepacia are the most
commonly recovered [1]. In 2008, phylogenetic analysis ofMicrobiol Infect 2015; 21: 150–156
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.07.014seven multilocus sequence typing (MLST) concatenated alleles
revealed two clusters within taxon K of Bcc, and two novel
species were described: B. contaminans and B. lata [4].
Here we report a large increase in the detection of B. con-
taminans in patients with CF in Spain. The aim of this study was
to describe the genetic diversity of B. contaminans isolates from
this population, to examine their relationships with other B.
contaminans isolates and other Bcc species, to determine their
susceptibility to antimicrobial agents and to compare the latter
with that recorded for other Bcc species isolated from similar
Spanish patients.Materials and methodsBacterial strains
Between 2008 and 2012, 166 Bcc isolates from 89 patients with
CF attending 18 Spanish hospitals were submitted for identiﬁ-
cation to the Taxonomy Laboratory at the Bacteriology Serviceious Diseases. Published by Elsevier Ltd. All rights reserved
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Spain). These were isolated from sputum (n = 160), bron-
choalveolar aspirate (n = 2), bronchoalveolar lavage, oropha-
ryngeal exudate, nasopharyngeal aspirate and nasopharyngeal
exudate (n = 1 each).
Species identiﬁcation
Bacterial identiﬁcation was performed by recA gene sequence
analysis [5]. Similarities of >99% with GenBank-deposited se-
quences were required for positive identiﬁcations. The se-
quences of B. cepacia isolates identiﬁed before the description
of B. contaminans and submitted to our laboratory between
1999 and 2009 (n = 18) were revised; eight of these (two from
2008 and six from 2009) belonged to the latter species and
were also included in this study.
Molecular typing
Genetic diversity was examined using MLST as previously
described [6]. Sequences were assembled and aligned using
Lasergene SeqMan II software and the ClustalW routine in the
Lasergene MegAlign suite (DNA Start Inc., Madison, WI).
Sequence types (STs) were assigned using the MLST website
(http://pubmlst.org/bcc/) tool. Minimum spanning tree (MST)
analysis was performed using PHYLOViZ software (http://
phylovit.net) to establish relationships between the STs found
in this study and B. contaminans STs on the MLST website.
Phylogenetic analysis of the seven MLST concatenated alleles was
performed by construction of a neighbour-joining (NJ) tree using
the Kimura two-parameter substitution model and using 1000
bootstrap replicates (performed using MEGA6 software) [7].
Isolates were also typed by pulsed-ﬁeld gel electrophoresis
(PFGE) after SpeI restriction as previously described [8]. In
order to run the different types on the same gel, each proﬁle
showing a difference in just one band was submitted to a second
round of SpeI PFGE. These PFGE types were analysed by
InfoQuest software (Applied Maths, Saint-Martens-Latem,
Belgium). Clustering was determined using the unweighted
pair-group method with arithmetic averages (UPGMA) and
Dice’s coefﬁcient (tolerance 0.6%). PFGE types were coded
with a number and, in the case of related strains (i.e. with a
genetic similarity of 80%), a lowercase letter.
The discriminatory abilities of MLST and PFGE were analysed
by calculating Simpson’s index of diversity (SID) and the cor-
responding 95% conﬁdence intervals (CIs) [9]. Calculations
were performed online using the appropriate Comparing Par-
titions tool (http://darwin.phylovit.net/ComparingPartitions/).
Susceptibility to antimicrobial agents
The minimum inhibitory concentrations of ceftazidime, piper-
acillin, imipenem, tobramycin, levoﬂoxacin and cotrimoxazoleClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologywere determined using the Etest (BioMérieux, Marcy-l’Etoile,
France). An inoculum of 0.5 McFarland was plated on Mueller-
Hinton medium and incubated at 37°C for 24 hours. Pseudo-
monas aeruginosa ATCC 27853 and Escherichia coli ATCC
25922 were used as control strains. The results were inter-
preted according to the criteria of the Clinical and Laboratory
Standards Institute for B. cepacia [10]. Intermediate values were
categorized as resistant. As a result of the lack of breakpoints
for imipenem, piperacillin and tobramycin, those corresponding
to meropenem for B. cepacia, and piperacillin and tobramycin
for P. aeruginosa were used [10]. The 50% and 90% minimum
inhibitory concentrations and the percentage resistance values
were calculated, taking into account those isolates showing
different PFGE types and susceptibility patterns. Susceptibility
differences between B. contaminans and the most prevalent Bcc
species in patients with CF identiﬁed by our reference labora-
tory [8] were examined by the chi-square test.
Study limitations
Clinical and other microbiologic data for the patients (e.g. lung
function scores, fever, worsening of general condition, isolation
of other pathogens along with B. contaminans, acquisition and
overgrowth of strains associated with CF pulmonary exacer-
bations) are not shown because our institution acts as a
reference centre for bacterial identiﬁcation, and this informa-
tion was not provided by the patients’ physicians.ResultsSpecies identiﬁcation
B. contaminanswas identiﬁed in 59 of the 166Bcc isolates received
from 2008 to 2012. Taking into account the ﬁrst Bcc isolate
recovered from each patient, the overall incidence of B. con-
taminans was 36.5% (n = 35) (Supplementary Table S1), whereas
for B. multivorans and B. cenocepacia it was 17.7% (n = 17) and
12.5% (n = 12), respectively. Five of the 35 patients experienced
the replacement of one Bcc species (B. cepacia, B. multivorans, B.
cenocepacia, B. stabilis, B. contaminans) by another (Fig. 1).
B. contaminans STs and genetic relationships
Four STs (SID = 0.681, 95% CI 0.632–0.731) were identiﬁed
among the 59 B. contaminans isolates: ST102 (25 isolates from
14 patients; incidence 38.9%), ST404 (14 from 10; incidence
27.8%), ST482 (18 from 10; incidence 27.8%) and ST771 (two
from two; incidence 5.5%). A new ST, coded by the MLST
database website as ST771, was detected. This differed from
ST482 in terms of its atpD allele: 178T/A.
The MST analysis of all B. contaminans isolates (clinical and
environmental) that have been characterized by MLST andand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 150–156
FIG. 1. Infection/colonization of patients with
cystic ﬁbrosis (n = 10) by Burkholderia con-
taminans clones and other species of the
Burkholderia cepacia complex.
152 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIsubmitted to the MLST website to date revealed nine groups,
six of which involved singleton STs (Fig. 2). Group I included
ST482, which has a global distribution, and four single-locus
variants: ST716 and ST771 (both detected only in Spain), and
ST286 and ST637 (detected in the United States and France,
respectively). Group II included ST100 from an isolate identiﬁed
in Canada, and a triple-locus variant, ST404, from isolates
recovered in Spain. Group III included ST123, ST197 (a single-
locus variant) and ST97 (a triple-locus variant); to date, none of
these has been detected in Spain. ST102, which formed a group
on its own, was the most common ST. It has been detected in
isolates from several countries and from the Sargasso Sea.
The NJ tree grouped all B. contaminans STs available in the
MLST database into a single branch with high bootstrap support
(Fig. 3). This branch showed three clusters, A, B and C, which
grouped between 15 and 21 isolates from various countries,
isolated both from the environment and from patients with CF.
The type strain for B. contaminans with ST102 fell into group B.
The percentage similarities among the concatenated alleles
within each group were 98.6% to 99.8% for group A, 99.1% for
B and 99.1% to 100% for C.
B. contaminans PFGE types
PFGE analysis showed 17 SpeI types (SID = 0.90, 95% CI
0.860–0.941) that were coded B1 to B17. Two isolates with
ST102 belonging to patients P45 and P51 were not digested by
SpeI. Genetic diversity ranged from 33.7% to 97% (Fig. 4).
Analysis revealed three large clusters: cluster I included 23
isolates with ST102 (genetic similarity 49.4 to 97%), cluster II
grouped 14 isolates with ST404 (genetic similarity 97%) andClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcluster III included 16 isolates with ST482 (genetic similarity
45.4–70.3%) plus two isolates with ST771. Four types—B4, B5,
B8 and B9—had two subtypes, while B3 had ﬁve subtypes.
Type B9 gathered strains with ST771 (B9a) and ST482 (B9b)
(genetic similarity 90.3%). B8 was the PFGE type with the
highest incidence (26.3%), followed by B3 and B9, with 10.5%
each.
B. contaminans antimicrobial susceptibility
Among the 50 isolates (those with different PFGE types and
susceptibility patterns), cotrimoxazole and ceftazidime were
the most active antibiotics, with resistance rates close to 15%,
followed by levoﬂoxacin and piperacillin (26% and 36%
respectively) (Table 1). As seen with B. multivorans and B. cen-
ocepacia, imipenem had little effect. The chi-square test iden-
tiﬁed signiﬁcant differences (p < 0.05) between B. contaminans
and B. multivorans and between B. contaminans and B. cen-
ocepacia with respect to ceftazidime, tobramycin, levoﬂoxacin
and cotrimoxazole resistance.DiscussionThis study records a notable overall incidence (36.5%) of B.
contaminans in Spanish patients with CF between 2008 and
2012. The annual incidence associated with this species
increased from 14.3% in 2008 to 72.2% in 2011 (Supplementary
Table S1). In contrast, the annual incidence values for B. multi-
vorans and B. cenocepacia—the most prevalent Bcc species in
such patients for many years [1]— fell during the same period:ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 150–156
FIG. 2. Minimum spanning tree of all Burkholderia contaminans sequence types (STs) held by the multilocus sequence typing (MLST) website (http://
pubmlst.org/bcc/). The size of each circle is related to the number of isolates submitted to the MLST website; colours indicate geographical origin; the
number on each line indicates the level of genetic relationship between STs (1 for single-locus variant and 3 for triple-locus variant; there is no double-
locus variant). ST102, ST404, ST482 and ST771 were detected in our study.
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cenocepacia from 35.7% in 2008 to 0% in 2012. The same has
been reported from Argentina [11], where B. contaminans is
now recovered from 57.6% of patients. Fig. 1 shows the
colonization/infection of patients by different Bcc species as
well as the replacement of STs and PFGE type variations. The
substitution of species and clonal replacement has been
described for other Bcc species [12], although there is no ev-
idence that the clinical status of patients is associated with Bcc
strain replacement [13].
The phylogenetic (NJ) analysis of the seven MLST concate-
nated alleles from the B. contaminans isolates and other Bcc
species (Fig. 3) showed that B. contaminans STs are part of a
robust branch occupying a single clade along with B. lata, with a
bootstrap value of 99 (the percentage similarity among the type
strain for B. lata and B. contaminans STs ranges 96.5–97.2%).
This topology agrees with a previous report describing two
novel species for taxon K [4].
The MST analysis showed that two of the STs detected, ST102
and ST482, may have a global distribution among patients withClinical Microbiology and Infection © 2014 European Society of Clinical MicrobiologyCF; certainly, they are also present in other countries of the
European Union, the United States and Australia (data from
MLST website). Further, a recent report identiﬁed these STs,
along with ST404, in bacteria from ﬁve patients attending a hos-
pital in Madrid, Spain [14]. The analysis also showed that most B.
contaminans STs are limited to a geographic location: ST97 and
197 in Australia, ST100 in France and ST716 and ST771 in Spain.
The recA-ST-71 allele, which is predominant in B. contaminans
isolated from Argentinian patients with CF [11], was detected in
B. contaminans isolates from the present patients (n = 10),
although recA-ST-89 (n = 14) and -152 (n = 12) were more
prevalent in our study. The new atpD-ST-318 allele detected in
the isolate with ST771 might have been derived via a point mu-
tation in atpD-ST-151 in patient P21; this patient was previously
recorded as infected with B. contaminans with ST482. Such mu-
tations, along with horizontal gene transfer, are characteristic of
environmental bacteria. In addition, the antimicrobial suscepti-
bility of both isolates was different with respect to ceftazidime,
piperacillin and levoﬂoxacin (for the isolate with ST482, 2, 4 and
2 μg/mL, respectively; and for the isolate with ST771, 256, >256and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 150–156
FIG. 3. Neighbour-joining tree inferred from
the seven multilocus sequence typing (MLST)
concatenated alleles, showing the phyloge-
netic relationships among members of the
Burkholderia cepacia complex (Bcc). The type
strains T of Bcc species were used for
comparison when their sequences were
available in the MLST database. The analysis
was performed by MEGA6 software and the
Kimura two-parameter method. The length
of the branches corresponds to the number
of base substitutions per site.
154 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIand >32 μg/mL respectively). Note that the susceptibility of
isolates with ST771 recovered from patients P21 and P17 (pre-
viously infected with B. cepacia), as well as the hospital involved
and the date of isolation, were the same. This suggests that
patient-to-patient transmission occurred, although acquisition
from a common source by both patients cannot be ruled out.
PFGE revealed wide genetic diversity for the B. contaminans
population, with 17 pulsotypes detected. Similar ﬁndings have
been described for B. cenocepacia isolates recovered from pa-
tients with CF in the Czech Republic [15]. No clustering of STs
and PFGE types linked to the geographical origin within Spain
were detected, but identiﬁcation of the same SpeI types inClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectpatients from different geographical locations (Fig. 2, types B1,
B3, B4, B8, B9 and B13) suggests that pathogen acquisition
might be via the environment, in which Bcc is ubiquitous [1], or
from contaminated products used in hospitals. In this regard,
hospital infections of patients with CF [16] and certain immu-
nocompromising conditions [17] have been described as asso-
ciated with the use of healthcare products.
A correlation between STs and PFGE clusters was detected
because each ST was grouped into a single cluster, except for
two isolates with ST482 that showed less genetic similarity
(33.7%) with the remaining isolates. However, the nonover-
lapping conﬁdence intervals for the Simpson’s index of diversityious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 150–156
FIG. 4. Genetic diversity of Bur-
kholderia contaminans isolates, char-
acterized by SpeI pulsed-ﬁeld gel
electrophoresis (clustering at 80%
similarity). All isolates were recov-
ered from Spanish patients with
cystic ﬁbrosis between 2008 and
2012. aCodes assigned according to
the date of submission of Burkholderia
spp. strains to our laboratory. bSe-
quence type.
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ities. The PFGE band heterogeneity detected has also been
described for B. cenocepacia isolates with ST32 and was
attributed to genomic rearrangements mediated by the move-
ment of insertion sequences [18].
Bcc species are characterized by their antibiotic multi-
resistance. However previous studies have shown that antimi-
crobial susceptibility is genomovar dependent [19]. In fact,
signiﬁcant differences (p < 0.05) were detected between B.TABLE 1. Susceptibilities to different antimicrobial agents of Burk
strains isolated from Spanish patients with cystic ﬁbrosis
Antimicrobial agent




Range 50%/90% Range 50%
Ceftazidimea 2 to >256 4/32 16.0 1 to >256 8/>
Piperacillinb 4 to >256 16/>256 36.0 1 to >256 64/
Imipenemc 1 to >32 16/>32 88.0 0.25 to >32 >32
Tobramycinb 0.50 to >256 8/>256 52.0 1 to >256 128
Levoﬂoxacina 0.25 to >32 1/16 26.0 0.5 to >32 4/>
Cotrimoxazolea 0.12 to >32 0.5/4 12.0 0.12 to >32 4/>
MIC, minimum inhibitory concentration; CLSI, Clinical and Laboratory Standards Institute.
aBreakpoints of CLSI for B. cepacia used.
bBreakpoints of CLSI for Pseudomonas aeruginosa used.
cBreakpoints for meropenem of CLSI for B. cepacia used.
dp value with respect to B. contaminans by chi-square test.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologycontaminans and other Bcc species with respect to ceftazidime,
tobramycin, levoﬂoxacin and cotrimoxazole resistance. The
ability to adapt to different levels of antibiotic challenge by the
acquisition and maintenance of resistance genes [20], and the
antibiotic pressure to which the most prevalent species are
exposed, may explain these differences. The antimicrobial sus-
ceptibility of isolates with identical PFGE type collected from
the same patient was similar, although a change from suscep-
tible to resistant for piperacillin, tobramycin and levoﬂoxacinholderia contaminans B. multivorans [8] and B. cenocepacia [8]
23) B. cenocepacia (n [ 20)
% R pd
MIC (μg/mL)
% R pd/90% Range 50%/90%
256 56.5d <0.05 2 to >256 4/>256 45.0d <0.05
>256 56.5 — 2 to >256 16/>256 50.0 —
/>32 87.0 — 8 to >32 >32/>32 95.0 —
/>256 91.3d <0.05 32 to >256 >256/>256 100d <0.05
32 56.5d <0.05 0.5 to >32 16/>32 70.0d <0.05
32 52.2d <0.05 0.25 to >32 4/>32 55.0d <0.05
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 150–156
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In addition, this increase in resistance coincided with PFGE type
variations for isolates collected from the following patients: P33
(types B7 and B3 with changes respect to ceftazidime and
cotrimoxazole); P43 (B15 and B11 with respect to tobramycin);
and P44 (B3c and B6 with respect to ceftazidime and levo-
ﬂoxacin). Information regarding the antibiotic therapies to
which these patients were subjected was not available, so no
relationship between the increase in resistance and antibiotic
pressure could be established.
In conclusion, three major STs of B. contaminans showing
high genetic diversity, as determined by PFGE, were detected in
Spanish patients with CF between 2008 and 2012. Despite
being more susceptible to the studied antimicrobial agents, the
overall incidence of these B. contaminans isolates is higher than
that for B. multivorans and B. cenocepacia. B. contaminans might
possess some ecologic advantages allowing it to increase its
presence in the patient’s environment or hospital facilities.
Moreover, clinical characteristics of patients with CF (e.g. age,
chronic colonization/infection, years of Bcc infection and clinical
deterioration) might inﬂuence the increase in B. contaminans
isolation.Transparency declarationAll authors report no conﬂicts of interest relevant to this
article.AcknowledgementsThe authors thank the clinical microbiologists involved in the
isolation and submission of the Bcc strains to the Taxonomy
Laboratory of the Bacteriology Service at the National Centre
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